Navigation Links
Bayer Announces Availability of Reformulated Liquid Leukine(R)
Date:5/19/2008

ket demand.

"At Bayer, providing effective and safe medicines for patients is our highest priority," said Paul MacCarthy, MD, FRCPI, vice president and head of U.S. Medical Affairs for Bayer HealthCare Pharmaceuticals. "Bayer is pleased to bring back to U.S. oncologists and hematologists an EDTA-free formulation of liquid Leukine for the care of their patients. Liquid Leukine without EDTA has been used in the treatment of more than 200,000 cancer patients." New data will be reported at the upcoming American Society for Clinical Oncology (ASCO) conference regarding the clinical impact of Leukine in cancer care.

The EDTA-free formulation of liquid Leukine is presented in Bayer HealthCare Pharmaceuticals' branded packaging. The product was previously marketed under the Berlex Laboratories brand. Berlex was acquired by Bayer.

Bayer has posted a Dear Health Care Provider letter, along with its enclosures, on its websites today at http://www.pharma.bayer.com, http://www.bayeroncology.com and http://www.leukine.com and will be mailing it to U.S. oncologists and hematologists who prescribe and use Leukine for their patients.

Customers seeking information on how to order the reformulated product may call Bayer HealthCare Pharmaceuticals toll free at 1-888-84Bayer (1-888-842-2937).

Leukine has been used to treat nearly 350,000 cancer patients in the United States since 1991. Among its indications, Leukine is the only myeloid growth factor approved to reduce the incidence of severe and life-threatening infections and infections resulting in death following induction chemotherapy in older adult patients (> 55 years of age) with AML and to prolong survival of patients have undergone allogeneic or autologous bone marrow transplantation (BMT) and are experiencing graft failure or engra
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. ACT Biotech Acquires Clinical and Early Stage Oncology Portfolio Licenses From Bayer Healthcare
2. United Nations Environment Programme and Bayer Corporation Announce North American Winners of International Childrens Painting Competition
3. Bayer/Schering-Plough/Shionogis Avelox Has Advantages Over Levofloxacin in the Treatment of Community-Acquired Pneumonia
4. Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement
5. Bayer to Receive Two Top National Awards for Its Science Education, Science Literacy Work
6. Bayer HealthCare and Juvaris BioTherapeutics Announce Major Licensing Agreement
7. 60 Minutes to Report on Dangers of Trasylol: Cory Watson Crowder & DeGaris Involved in Litigation Against Pharmaceutical Giant Bayer AG
8. Bayer Establishes US Special Access Program for Leukine(R) While Replacing Current Liquid Formulation
9. Bayer Corporation Renames Its U.S. Foundation, Refocuses Charitable Giving Areas
10. New Bayer, United Nations Partnership Brings International Environment and Art Competition to Local Elementary and Middle Schools
11. New Bayer, United Nations Partnership Brings International Environment and Art Competition to Pittsburgh-Area Elementary and Middle Schools
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... CO (PRWEB) November 22, 2014 ... growth equity investments in the consumer brand sector, ... The investment will be used to help fund ... product pipeline rollout, particularly its proprietary apparel and ... will join BackJoy’s Board of Directors. , BackJoy ...
(Date:11/22/2014)... A Xarelto lawsuit has been filed on behalf of ... in damages from the makers and marketers of the ... woman began using Xarelto in March 2012 and used it ... suffered life-threatening bleeding in July 2012 and as a result, ... distress. The lawsuit purports that the woman’s injuries are due ...
(Date:11/22/2014)... Nov. 21, 2014 (HealthDay News) -- The widely used ... death and hospitalization among patients who have the heart ... failure, a new study finds. Atrial fibrillation is ... linked to a rise in risk for stroke among ... a century to help treat irregular heartbeat, the authors ...
(Date:11/21/2014)... Nov. 20, 2014 (HealthDay News) -- Seeking to make ... U.S. Food and Drug Administration on Thursday approved a ... Hydrocodone -- best known by the brand name ... been tied to a surge in dangerous addictions across ... approved Hysingla ER (hydrocodone bitartrate) is an extended-release tablet ...
(Date:11/21/2014)... MLF Biotech, Inc. has developed a ... Probiotics for Pets helps maintain digestive health and can ... intestinal flora after it experiences a period of stress, ... for Pets is a proprietary blend of pure probiotics ... active bacteria strains that are safe and effective for ...
Breaking Medicine News(10 mins):Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 3Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 2Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 3Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 4Health News:Treating Irregular Heartbeat With Digoxin May Come With Risks 2Health News:Treating Irregular Heartbeat With Digoxin May Come With Risks 3Health News:FDA Approves 'Abuse-Resistant' Narcotic Painkiller 2Health News:FDA Approves 'Abuse-Resistant' Narcotic Painkiller 3Health News:MLF Biotech Introduces Liv-Pro Probiotics for Pets 2
... , BIRMINGHAM, Ala., Aug. 19 ... more individuals, organizations, and society will continue to ... and communication technology or (ICT). With an ever-expanding ... GASICORP, worldwide leader in information and communication technology, ...
... CHICAGO, Aug. 19 As Electronic Health Record (EHR) Solution Providers race ... e ntric, Inc , offers practical advice for evaluating and designing ... We b i nars will highlight techniques used ... clinician performance while increasing adoption. , , Measuring and improving ...
... NEW YORK, Aug. 19 Bayard Advertising Agency, Inc., ... clients in a broad array of industries, announces its selection ... (HCA) West Florida Division. , , ... notes Jennifer Berres, VP Human Resources for HCA West Florida ...
... ... have a healthier lifestyle by health experts from Avon Obesity Service. , ... (PRWEB) August 19, 2009 -- A smoking alternative has been suggested ... ,Patients have been introduced to the Intellicig electronic cigarettes at Avon Obesity ...
... Biotech Ltd.,(NYSE Amex: SVA ), a leading developer and provider ... and six-,month periods ended June 30, 2009. , , ... to $20.0 million, -- Sales for the six-month period ... the quarter rose 52% to $10.7 million, -- Operating ...
... responsible for more than two thirds of the total ... newly adapted low-dose technique called adaptive statistical iterative reconstruction ... from CT up to 65 percent, according to a ... American Journal of Roentgenology (AJR). Iterative ...
Cached Medicine News:Health News:Are You Connected? AIM and GASICORP Expand Global Reach Through Landmark Strategic Alliance 2Health News:Are You Connected? AIM and GASICORP Expand Global Reach Through Landmark Strategic Alliance 3Health News:User Centric to Present Health IT Usability Webinar Series 2Health News:Bayard Advertising Appointed by Hospital Corporation of America (HCA) West Florida Division for Recruitment Advertising and Employment Branding 2Health News:Health Experts Praise Intellicig Electronic Cigarette 2Health News:Health Experts Praise Intellicig Electronic Cigarette 3Health News:Sinovac Reports Unaudited Second Quarter 2009 Financial Results 2Health News:Sinovac Reports Unaudited Second Quarter 2009 Financial Results 3Health News:Sinovac Reports Unaudited Second Quarter 2009 Financial Results 4Health News:Sinovac Reports Unaudited Second Quarter 2009 Financial Results 5Health News:Sinovac Reports Unaudited Second Quarter 2009 Financial Results 6Health News:Sinovac Reports Unaudited Second Quarter 2009 Financial Results 7Health News:Sinovac Reports Unaudited Second Quarter 2009 Financial Results 8Health News:Sinovac Reports Unaudited Second Quarter 2009 Financial Results 9Health News:Sinovac Reports Unaudited Second Quarter 2009 Financial Results 10Health News:Sinovac Reports Unaudited Second Quarter 2009 Financial Results 11Health News:Sinovac Reports Unaudited Second Quarter 2009 Financial Results 12Health News:Sinovac Reports Unaudited Second Quarter 2009 Financial Results 13Health News:Sinovac Reports Unaudited Second Quarter 2009 Financial Results 14
(Date:11/22/2014)... 2014 Research and Markets  has announced the ... Report, 2014-2017" report to their offering. ... recombinant protein drug market has been expanding rapidly owing ... the like. During 2005-2013, sales of recombinant protein drugs ... of 19.1%, and it is projected that ...
(Date:11/21/2014)... SAN DIEGO , Nov. 21, 2014 /PRNewswire/ ... TNDM ), a medical device company and ... today announced a partnership with Tidepool, a non-profit ... an open source software platform that increases diabetes ... the Tidepool Platform, which is currently under development, ...
(Date:11/21/2014)... , Nov. 21, 2014  Abaxis, Inc. (NasdaqGS: ... point-of-care instruments and consumables for the medical, research, and ... the veterinary and research markets in the ... a stock purchase agreement to acquire 100% of QCR ... based distribution organization. The transaction closed on ...
Breaking Medicine Technology:China Recombinant Protein Drug Industry Report, 2014-2017 2China Recombinant Protein Drug Industry Report, 2014-2017 3Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 2Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 3Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4
... Inc.,(NYSE:MDT) today announced that a review of ... that the trial has met its primary,non-inferiority ... a randomized, single-blind,trial evaluating the safety and ... as compared to the TAXUS Paclitaxel-Eluting,Coronary Stent ...
... Cardiovascular Target from Lexicon's Genetic,Research -, ... /PRNewswire-FirstCall/ --,Lexicon Pharmaceuticals, Inc. today reported ... directed to a,potential new target, angiopoietin-like ... cholesterol. Research suggests that,a monoclonal antibody ...
Cached Medicine Technology:ENDEAVOR IV Clinical Trial Meets Primary Endpoint 2Lexicon Develops Antibodies That Lower Triglycerides and,Cholesterol as Potential New Therapy for Heart Disease 2Lexicon Develops Antibodies That Lower Triglycerides and,Cholesterol as Potential New Therapy for Heart Disease 3Lexicon Develops Antibodies That Lower Triglycerides and,Cholesterol as Potential New Therapy for Heart Disease 4Lexicon Develops Antibodies That Lower Triglycerides and,Cholesterol as Potential New Therapy for Heart Disease 5
Non-dissolvable Herrick Lacrimal Plugs provide long-term lacrimal occlusion through partial blockage of the horizontal canaliculus....
Provides quick freezing and quick defrosting. Lightweight probe tips have high conductivity silver. Useful for Cataract, Retinal Detachment, Glaucoma and Intra-vitreal surgery. Includes either one ca...
Khosla Precision and Quality in Medical and Surgical Products....
Khosla Precision and Quality in Medical and Surgical Products....
Medicine Products: